Phase II study of orally and rectally administered Tegafur in liver metastases from gastric carcinoma.
Twenty-four eligible and evaluable patients with measurable liver metastases from gastric cancer were treated with oral or rectal Tegafur. Objective responses were seen in 8 of the patients (33.3%), lasting between 1.5 and 15 months. The median survival period was 10 months for the responders and 2.6 months for non-responders. No complete response was observed. The survival of responders was significantly longer than that of non-responders (p less than 0.01). Toxicity was mild and consisted principally of gastrointestinal and hematological side effects. No central nervous system toxicity was seen.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008297:Male; D008875:Middle Aged; D012007:Rectum; D013274:Stomach Neoplasms; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced
D005641:Tegafur; D005472:Fluorouracil